Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.60 |
| ▸ | RAB9A | P51151 | 12/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 8/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030288 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 | |
| SCHEMBL4024862 | 0.87 | PPARA (0.56) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 | |
| SCHEMBL4033814 | 0.86 | PPARA (0.58) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 | |
| SCHEMBL3771944 | 0.85 | RAB9A (0.58) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 | |
| SCHEMBL10520054 | 0.85 | RAB9A (0.46) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 | |
| SCHEMBL9593485 | 0.83 | RAB9A (0.57) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 | |
| SCHEMBL21939050 | 0.80 | RAB9A (0.66) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 | |
| SCHEMBL20020277 | 0.80 | RAB9A (0.54) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 | |
| SCHEMBL2328124 | 0.80 | NOTUM (0.43) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 | |
| SCHEMBL15931414 | 0.79 | HPGD (0.58) | SMN1; SMN2RAB9AHPGDNPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247288-A1 | Method for manufacturing isoxazole derivative or dihydroisoxazole derivative | GAKUIN, RIKKYO (JP) | 2006-11-02 | — | — | US | claimed |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-07-02 | — | — | US | disclosed |
| EP-1937264-B1 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK SHARP & DOHME (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7893091-B2 | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence | MERCK SHARP & DOHME CORP. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893091-B2 | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence | MERCK SHARP & DOHME CORP. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| US-7495107-B2 | Method for manufacturing isoxazole derivative or dihydroisoxazole derivative | RIKKYO GAKUIN (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7468437-B2 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468437-B2 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2007044296-A2 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK & CO., INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060247288-A1 | Method for manufacturing isoxazole derivative or dihydroisoxazole derivative | GAKUIN, RIKKYO (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247288-A1 | Method for manufacturing isoxazole derivative or dihydroisoxazole derivative | CYP3A7, NDUFS7, IDH3A | SMN1; SMN2 4090/4885RAB9A 4172/4885HPGD 689/4885 |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | HDAC1, HDAC7, HDAC5 | SMN1; SMN2 1895/4885RAB9A 3328/4885HPGD 161/4885 |
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MME, UTS2R, BPHL | SMN1; SMN2 2070/4885RAB9A 3885/4885HPGD 288/4885 |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | TACR1, NPSR1, TACR2 | SMN1; SMN2 4061/4885RAB9A 4258/4885HPGD 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.